Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo

    Stakišaitis D (1,2), Juknevičienė M (3), Damanskienė E (3), Valančiūtė A (3), Balnytė I (3), Alonso MM (4).

    (1) Laboratory of Molecular Oncology, National Cancer Institute, 08660 Vilnius, Lithuania.
    (2) Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
    (3) Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
    (4) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, 55 Pamplona, Spain.

    Cancers 20 de AGOSTO de 2019

  • The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Martínez-Vélez N (1,2,3), Garcia-Moure M (1,2,3), Marigil M (1,2,3), González-Huarriz M (1,2,3), Puigdelloses M (1,2,4), Gallego Pérez-Larraya J (1,2,4), Zalacaín M (1,2,3), Marrodán L (1,2,3), Varela-Guruceaga M (1,2,3), Laspidea V (1,2,3), Aristu JJ (1,5), Ramos LI (1,5), Tejada-Solís S (1,6), Díez-Valle R (1,6), Jones C (7,8), Mackay A (7,8), Martínez-Climent JA (1,9), García-Barchino MJ (1,9), Raabe E (10,11), Monje M (12), Becher OJ (13), Junier MP (14), El-Habr EA (14), Chneiweiss H (14), Aldave G (15), Jiang H (16), Fueyo J (16,17), Patiño-García A (1,2,3), Gomez-Manzano C (18), Alonso MM (19,20,21).

    (1) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (8) Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (9) Division of Hematopoietic Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, CIBERONC, Pamplona, Pamplona, Navarra, Spain.
    (10) Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (11) Division of Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (12) Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
    (13) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (14) CNRS UMR8246, Inserm U1130, Neuroscience Paris Seine - IBPS, Sorbonne Universities, Paris, France.
    (15) Division of Pediatric Neurosurgery, Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
    (16) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (17) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (18) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (19) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (20) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (21) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.

    Nature Communications 28 de MAYO de 2019

  • Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    Martinez-Velez N (1,2,3), Marigil M (1,2,3,4), García-Moure M (1,2,3), Gonzalez-Huarriz M (1,2,3), Aristu JJ (1,5), Ramos-García LI (5), Tejada S (1,2,6), Díez-Valle R (1,2,6), Patiño-García A (1,2,3), Becher OJ (7), Gomez-Manzano C (8,9), Fueyo J (8,10), Alonso MM (11,12,13).

    (1) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.
    (4) Division of Neurosurgery, Lariboisière University Hospital, 2 Rue Ambroise Paré, 75475, Paris, cedex 10, France.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (7) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (8) Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (9) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (10) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (11) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (12) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (13) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.

    Acta Neuropathologica Communications 29 de ABRIL de 2019

  • Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models

    Collantes M (1,2), Martínez-Vélez N (3), Zalacain M (3,2), Marrodán L (3,2), Ecay M (4), García-Velloso MJ (1,2), Alonso MM (3,2), Patiño-García A (3,2), Peñuelas I (5,6,7).

    (1) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Avenida Pío XII, 36 31008, Pamplona, Spain.
    (2) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (3) Departamento de Pediatría, Clínica Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (4) Small Animal Imaging Research Unit, CIMA, Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (5) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Avenida Pío XII, 36 31008, Pamplona, Spain.
    (6) Small Animal Imaging Research Unit, CIMA, Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (7) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

    BMC Cancer 29 de NOVIEMBRE de 2018

  • Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

    Lang FF (1), Conrad C (1), Gomez-Manzano C (1), Yung WKA (1), Sawaya R (1), Weinberg JS (1), Prabhu SS (1), Rao G (1), Fuller GN (1), Aldape KD (1), Gumin J (1), Vence LM (1), Wistuba I (1), Rodriguez-Canales J (1), Villalobos PA (1), Dirven CMF (1), Tejada S (1), Valle RD (1), Alonso MM (1), Ewald B (1), Peterkin JJ (1), Tufaro F (1), Fueyo J (1).

    (1) Frederick F. Lang, Charles Conrad, Candelaria Gomez-Manzano, W.K. Alfred Yung, Raymond Sawaya, Jeffrey S. Weinberg, Sujit S. Prabhu, Ganesh Rao, Gregory N. Fuller, Kenneth D. Aldape, Joy Gumin, Luis M. Vence, Ignacio Wistuba, Jaime Rodriguez-Canales, Pamela A. Villalobos, and Juan Fueyo, The University of Texas MD Anderson Cancer Center; Brett Ewald, Joanna J. Peterkin, and Frank Tufaro, DNAtrix, Houston, TX; Clemens M.F. Dirven, Erasmus University Medical Center, Rotterdam, the Netherlands; and Sonia Tejada, Ricardo D. Valle, and Marta M. Alonso, Clínica Universidad de Navarra, Pamplona, Spain.

    Journal of Clinical Oncology 12 de FEBRERO de 2018

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra